Management of viral hepatitis in liver transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Soung Won | - |
dc.contributor.author | Choi, YoungRok | - |
dc.contributor.author | Kim, Jin-Wook | - |
dc.date.accessioned | 2021-08-11T21:46:38Z | - |
dc.date.available | 2021-08-11T21:46:38Z | - |
dc.date.issued | 2014-12 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/11690 | - |
dc.description.abstract | Recurrence of viral hepatitis after liver transplantation (LT) can progress to graft failure and lead to a decrease in longterm survival. Recently, there have been remarkable improvement in the treatment of chronic hepatitis B (CHB) using potent antiviral agents. Combination of hepatitis B immunoglobulin and potent antiviral therapy has brought marked advances in the management of CHB for liver transplant recipients. Post-transplant antiviral therapy for hepatitis C virus infection is generally reserved for patients showing progressive disease. Acheiving a sustained virological response in patients with LT greatly ameliorates graft and overall survival, however this only occurs in 30% of transplant recipient using pegylated interferon and ribavirin (RBV). Direct acting antivirals such as protease inhibitors, polymerase or other non-structural proteins inhibitors are anticipated to establish the new standard of care for transplant recipients. In liver transplant recipients, hepatitis E virus infection is an uncommon disease. However, it can lead to chronic hepatitis and cirrhosis and may require retransplantation. Recently, 3-month course of RBV monotherapy has been reported as an effective treatment. This review focuses on the recent management and therapeutic approaches of viral hepatitis in liver transplant recipient. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간학회 | - |
dc.title | Management of viral hepatitis in liver transplant recipients | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3350/cmh.2014.20.4.338 | - |
dc.identifier.wosid | 000409421100002 | - |
dc.identifier.bibliographicCitation | Clinical and Molecular Hepatology, v.20, no.4, pp 338 - 344 | - |
dc.citation.title | Clinical and Molecular Hepatology | - |
dc.citation.volume | 20 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 338 | - |
dc.citation.endPage | 344 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordAuthor | Liver transplantation | - |
dc.subject.keywordAuthor | Viral hepatitis | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Management | - |
dc.subject.keywordAuthor | Antiviral therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.